Strategic Intelligence: Pharma M&A Deals H1 2026 - Top Themes

Strategic Intelligence: Pharma M&A Deals H1 2026 - Top Themes

Summary

This report analyzes the disruptive themes that have driven M&A activity in H1 2026 in the pharma Sector.

Key Highlights

• The global pharma sector in H1 2026 witnessed deals worth $186 billion, a growth of 154% compared to H1 2025. The Pharma sector recorded deal value worth $162 billion mega deals (defined as any deal valued at more than $1 billion) in H1 2026, an increase of 173% compared to H1 2025.

Scope

• This report provides an overview of merger and acquisition activity globally in H1 2026 in Pharma Sector
• It identifies the themes driving most notable to deals announced in H1 2026 in the Pharma Sector

Reasons to Buy

• Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&A).
• In this report we have listed down the most notable deals in pharma sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future.